A randomised trial comparing low dose vaginal misoprostol and dinoprostone for labour induction.
OBJECTIVE
To compare vaginal misoprostol with dinoprostone for induction of labour.


METHODS
Randomised multicentre trial.


METHODS
Labour wards of one university hospital and two teaching hospitals.


METHODS
Six hundred and eighty-one women with indication for labour induction at >or=36 weeks of gestation, singleton pregnancy and no previous ceasarean section.


METHODS
Misoprostol (25 mcg, hospital-prepared capsule) in the posterior vaginal fornix, every four hours, maximum three times daily or dinoprostone gel (1 mg) every four hours. Oxytocin was administered if necessary.


METHODS
Primary: 'adverse neonatal outcome' (5-minute Apgar score <7 and/or umbilical cord pH <7.15). Secondary: labour duration, mode of delivery and patient satisfaction.


RESULTS
Three hundred and forty-one women received misoprostol and 340 dinoprostone. The median induction-delivery interval was longer in the misoprostol group compared with the dinoprostone group (25 versus 19 hours, P= 0.008). The caesarean section rate was lower in the misoprostol group: 16.1%versus 21%, but this difference was not statistically significant RR = 0.8 (95% CI 0.6-1.04). 'Adverse neonatal outcome' was found to be similar in both groups: 21% in the misoprostol and 23% in the dinoprostone groups. Significantly fewer neonates were admitted to NICU in the misoprostol group compared with dinoprostone 19%versus 26% (RR = 0.7, 95% CI 0.5-0.98).


CONCLUSIONS
Misoprostol in this dosing regimen is a safe method of labour induction. NICU admission rates were lower in the misoprostol group. No difference could be detected in patient satisfaction between groups.
van Gemund
N
N
Department of Obstetrics, Leiden University Medical Centre, The Netherlands.
Scherjon
S
S
LeCessie
S
S
van Leeuwen
J H Schagen
JH
van Roosmalen
J
J
Kanhai
H H H
HH
D000282:Administration, Intravaginal; D000293:Adolescent; D000328:Adult; D001034:Apgar Score; D002214:Capsules; D002585:Cesarean Section / Q000706:statistics & numerical data; D002985:Clinical Protocols; D015232:Dinoprostone / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D005312:Fetal Blood; D005782:Gels; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007262:Infusions, Intravenous; D007751:Labor, Induced / Q000379:methods*; D016595:Misoprostol / Q000008:administration & dosage*; D010120:Oxytocics / Q000008:administration & dosage*; D010298:Parity; D017060:Patient Satisfaction; D011247:Pregnancy; D011256:Pregnancy Outcome; D011263:Pregnancy Trimester, Third
D002214:Capsules; D005782:Gels; D010120:Oxytocics; D016595:Misoprostol; D015232:Dinoprostone